STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 501–600 of 1,004
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer
Xiao, G.-Y., Tan, X., Rodriguez, B. L., Gibbons, D. L., Wang, S., Wu, C., Liu, X., Jiang, Y. Y., Vasquez, M. E., Tran, H. T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2220276120 · Cited by 38
“While our findings are relevant to acquired resistance to immune check-point blockade in Kras/p53-mutant LUAD (7, 41, 42), our study did not address other genetic contexts, such as KRAS/LKB1-mutant LUAD, which demonstrates immunologically cold phenotypes (43).”
Self-citationSalehi‐Rad, R., Lim, R. J., Du, Y., Tran, L. M., Li, R., Ong, S. L., Huang, Z. L., Dumitras, C., Zhang, T.-H., Park, S. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006896 · Cited by 39
“…with our previous findings, IT CCL21-DC and anti- PD-1 monotherapies elicited moderate antitumor efficacy in the KPL-3M model, whereas the combination therapy resulted in a synergistic antitumor response with eradication of approximately 40% of tumors (figure 1C, online supplemental figure S1F).”
Sun, L., Handorf, E. A., Zhou, Y., Borghaei, H., Aggarwal, C., & Bauman, J. R. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107510 · Cited by 42
Update on emerging biomarkers in lung cancer
Bernicker, E., Allen, T. C., & Cagle, P. T. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.01.46 · Cited by 36
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver
Kim, S. Y., & Halmos, B. (2020) · Lung Cancer Management · doi:10.2217/lmt-2020-0003 · Cited by 33
Nicoś, M., Krawczyk, P. A., Crosetto, N., & Milanowski, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.569202 · Cited by 34
“3 mut/Mb on average, respectively) (49).”
Federico, A. D., Giglio, A. D., Parisi, C., Gelsomino, F., & Ardizzoni, A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103302 · Cited by 36
DNA repair pathways and their roles in drug resistance for lung adenocarcinoma
Kara, A., Özgür, A., Nalbantoğlu, S., & Karadağ, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06314-z · Cited by 37
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 36
“[71] retrospectively assessed 17 KRAS mutant NSCLC treated with nivolumab, showing poorer responses in cases of KRAS/STK11 co-mutation compared to those with KRAS/TP53 co-mutation.”
Chen, H., Huang, D., Lin, G., Yang, X., Zhuo, M., Chi, Y., Zhai, X., Jia, B., Wang, J., Wang, Y., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4739 · Cited by 39
Self-citationMalhotra, J. D., Ryan, B. M., Patel, M. M., Chan, N., Guo, Y., Aisner, J., Jabbour, S. K., & Pine, S. R. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1377 · Cited by 42
“…resistance to PD-1 3 [20] Lymphocyte depleted (C4) 8 [7] 2 [13] 0 [0] 1 [7] Immunologically quiet (C5) – – – – TCGA, The Cancer Genome Atlas; IFNg, interferon-gamma; TGF-β , transforming growth factor-beta. blockade in NSCLC tumors with co-mutation in KRAS (the most common driver mutation) (9).”
InfluentialKarimi, N., & Moghaddam, S. J. (2023) · Cells · doi:10.3390/cells12050749 · Cited by 39
Paredes, R., Borea, R., Drago, F., Russo, A., Nigita, G., & Rolfo, C. D. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012288 · Cited by 44
Targeting STING to generate therapeutic anti-tumor immunity
Fahey, C. G., Cordova, A. F., Gedeon, P. C., & Barbie, D. A. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.002 · Cited by 43
Mascarenhas, E., Gelatti, A. C. Z., Araujo, L. H., Baldotto, C. S. D. R., Mathias, C., Zukin, M., Werutsky, G., Pacheco, P., Gomes, R., de Castro, G., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13777 · Cited by 40
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway
Carrot‐Zhang, J., Yao, X., Devarakonda, S. H. K., Deshpande, A. S., Damrauer, J. S., Silva, T. C., Wong, C. K., Choi, H. Y., Felau, I., Robertson, A. G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108707 · Cited by 39
“Alterations in STK11 in KRAS-driven LUADs have been shown to be associated with immune exclusion and a poor response to immunotherapies (Skoulidis et al., 2018).”
BackgroundSelf-citationShang, C., Huang, J., & Guo, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.677831 · Cited by 32
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 41
“Co-mutations of KRAS with STK11/LKB1 were associated with a lower response to immune checkpoint blockade, poor immune micro-environment, and low PD-L1 expression proved to be immune-inert tumors [19,20].”
BackgroundInfluentialZhang, W., Quan, Y., Ma, X., Zeng, L., Li, J., Chen, S., Su, M., Hong, L., Li, P., Wang, H., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102608 · Cited by 33
Tomlins, S. A., Khazanov, N. A., Bulen, B. J., Hovelson, D. H., Shreve, M. J., Lamb, L. E., Matrana, M. R., Burkard, M. E., Yang, E. S.-H., Edenfield, W. J., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00243-7 · Cited by 32
Peng, J., Zou, D., 龚五星, Kang, S., & Han, L. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1734156 · Cited by 33
“In this study, we demonstrated that two somatic mutation-based DNN classifications, C1 and C2 sub-groups, were potentially associated with the DCB and NDB of anti-PD-1/PD-L1 therapy in patients with LUAD.”
BackgroundInfluentialPorter, L., & McCaughan, F. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.007 · Cited by 32
Immunotherapies in clinical development for biliary tract cancer
Vogel, A., Bathon, M., & Saborowski, A. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1868437 · Cited by 31
“Potential candidates, however, include mutations leading to an activation of tumor-intrinsic WNT/b-catenin signaling, which are enriched in non-T-cell-inflamed tumors across multiple entities [57], or mutations in STK11, that are associated with a lack of clinical response to IO in lung cancer [58].”
BackgroundCucurull, M., Notario, L., Sánchez‐Céspedes, M., Hierro, C., Estival, A., Carcereny, E., & Saigí, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.793121 · Cited by 36
Olivares-Hernández, A., del Barco, E., Pérez, C. P., Miramontes‐González, J. P., Figuero-Pérez, L., Gómez, T. M., Cornejo, R. A. E., Hernández, L. B., González‐Sarmiento, R., Cruz, J. J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10020360 · Cited by 32
Imaging immunity in patients with cancer using positron emission tomography
Hegi‐Johnson, F., Rudd, S. E., Hicks, R. J., Ruysscher, D. D., Trapani, J. A., John, T., Donnelly, P. S., Blyth, B. J., Hanna, G. G., Everitt, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00263-x · Cited by 35
The DNA damage induced immune response: Implications for cancer therapy
Barros, E. M., McIntosh, S., & Savage, K. I. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103409 · Cited by 40
Reck, M., Popat, S., Grohé, C., Corral, J., Novello, S., Gottfried, M., Brueckl, W. M., Radonjic, D., Kaiser, R., & Heymach, J. V. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.009 · Cited by 37
Self-citationAlessi, J. V., Ricciuti, B., Wang, X., Pecci, F., Federico, A. D., Lamberti, G., Elkrief, A., Rodig, S. J., Lebow, E. S., Eicholz, J. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39874-8 · Cited by 33
Self-citationAhmed, J., Das, B., Shin, S. J., & Chen, A. P. (2023) · Cancers · doi:10.3390/cancers15245841 · Cited by 44
“For example, in melanoma, mutations in JAK1 / JAK2 (Janus Kinase 1/2) and B2M (beta-2-microglobulin) genes associated with acquired resistance to ICIs, and STK11 / LKB1 mutations in KRAS mutated lung adenocarcinoma, have been documented [67,68].”
BackgroundLee, H. M., Muhammad, N., Lieu, E. L., Cai, F., Mu, J., Ha, Y., Cao, G., Suchors, C., Joves, K., Chronis, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01066-z · Cited by 37
“KL NSCLC represents about one-third of mutant-KRAS-driven lung tumours and is associated with poor outcomes owing to resistance to chemotherapy and immune checkpoint therapy 58,59 .”
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
Konen, J. M., Rodriguez, B. L., Fradette, J. J., Gibson, L., Davis, D. H., Minelli, R., Peoples, M. D., Kovacs, J. J., Carugo, A., Bristow, C. A., et al. (2019) · Cancers · doi:10.3390/cancers11040462 · Cited by 31
“Patients that present with a p53 mutation concurrently with oncogenic Kras (KP) exhibit higher expression of PD-L1 and other inflammatory markers when compared to other commonly co-occurring mutations such as STK11/LKB1 or CDKN2A [17], and these patients respond better to PD-1/PD-L1 axis blockade [18].”
BackgroundIivanainen, S., & Koivunen, J. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020556 · Cited by 30
“Studies have shown the negative predictive value of STK11 mutations in NSCLC for ICIs either in monotherapy or in combination with chemotherapy [74].”
BackgroundTumor Milieu Controlled by RB Tumor Suppressor
Kitajima, S., Li, F., & Takahashi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072450 · Cited by 31
You, W., Shang, B., Sun, J., Liu, X., Su, L., & Jiang, S. (2020) · Oncology Reports · doi:10.3892/or.2020.7643 · Cited by 36
“Lastly, several studies revealed primary resistance to anti-PD-1/PD-L1 in tumors with specific mutations, for example LKB1 loss, which may be ascribed to the impaired antitumor immune responses (81,82).”
BackgroundMichaelidou, K., Koutoulaki, C., Mavridis, K., Vorrias, E., Papadaki, M. A., Koutsopoulos, A. V., Mavroudis, D., & Agelaki, S. (2020) · Cells · doi:10.3390/cells9112514 · Cited by 33
Shang, X., Li, Z., Sun, J., Zhao, C., Lin, J., & Wang, H. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.010 · Cited by 30
Targeting KRAS in Non-Small Cell Lung Cancer
Corral de la Fuente, E., Olmedo Garcia, M. E., Gomez Rueda, A., Lage, Y., & Garrido, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.792635 · Cited by 30
“4%), identifying STK11 as an antiPD-1 resistance mutation (28).”
BackgroundShen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 33
“Moreover, PD-L1 expression was also suppressed in cancer cells, indicating that STK11-deficient KRAS mutations lead to anti-PD-1/PD-L1 resistance in cancer cells (110, 115).”
BackgroundGarcia, B. N. C., van Kempen, L. C. L. T., Kuijpers, C. C. H. J., Schuuring, E. M. D., Willems, S. M., & van der Wekken, A. J. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.015 · Cited by 34
Ebot, E. M., Duncan, D. L., Tolba, K. A., Fabrizio, D. A., Frampton, G. M., Comment, L. A., & Albacker, L. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00286-4 · Cited by 37
Self-citationTumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
Li, H., Zhang, Y., Xu, Y., Huang, Z., Cheng, G., Xie, M., Zhou, Z., Yu, Y., Xi, W., & Fan, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05510-4 · Cited by 35
“Unfortunately, clinical data suggest that some NSCLC patients harbored classic gene mutations, such as EGFR mutations and STK11 / KRAS co-mutations, may poorly respond to ICIs [5, 6].”
Kundu, S. T., Rodriguez, B. L., Gibson, L. A., Warner, A. N., Perez, M. G., Bajaj, R., Fradette, J. J., Class, C. A., Solis, L. M., Alvarez, F. R. R., et al. (2022) · Genes & Development · doi:10.1101/gad.349321.121 · Cited by 32
Self-citationJulian, C., Pal, N., Gershon, A., Evangelista, M., Purkey, H., Lambert, P., Shi, Z., & Zhang, Q. (2023) · BMC Cancer · doi:10.1186/s12885-023-10778-6 · Cited by 31
Qu, F., Zhou, Y., & Wu, S. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02482-w · Cited by 38
“It is worth noting that about 30% of Kras-mutated NSCLC exhibit lower PD-L1 expression and less tumour-killing immune cell invasion due to SKT11/LKB11 co-mutation, which may lead to poor ICIs ef fi cacy [111, 112].”
BackgroundPreclinical development and clinical studies of targeted JAK/STAT combined Anti-PD-1/PD-L1 therapy
Chen, M., & Wang, S.-L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111717 · Cited by 30
Yu, J., Kong, X., & Feng, Y. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.14 · Cited by 73
Dai, H., Wang, X., Wu, Q., Tan, Y., Shen, H., Gu, Y., Su, C., & Chen, A. (2025) · Cell Division · doi:10.1186/s13008-025-00172-y · Cited by 33
“Most lung adenocarcinomas also carry mutations in KrasG12D or lack a recognizable driver oncogene [11, 12].”
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
Li, W., Peng, A., Wu, H., Quan, Y., Li, Y., Lu, L., & Cui, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601497 · Cited by 34
IFN-γ and CD38 in Hyperprogressive Cancer Development
Angelicola, S., Ruzzi, F., Landuzzi, L., Scalambra, L., Gelsomino, F., Ardizzoni, A., Nanni, P., Lollini, P., & Palladini, A. (2021) · Cancers · doi:10.3390/cancers13020309 · Cited by 34
Li, T., Wang, H., Xu, J., Li, C., Zhang, Y., Wang, G., Liu, Y., Cai, S., Fang, W., Li, J., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211038477 · Cited by 36
Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy
Halima, A., Vuong, W., & Chan, T. A.-T. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154945 · Cited by 38
“In addition, patients with positive PD-L1 also had worse outcomes if they had an STK11/LKB1 alteration (71).”
BackgroundKatiyar, V., Chesney, J. A., & Kloecker, G. H. (2023) · Cancers · doi:10.3390/cancers15143733 · Cited by 32
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
Berland, L., Gabr, Z., Chang, M., Ilié, M., Hofman, V., Rignol, G., Ghiringhelli, F., Mograbi, B., Rashidian, M., & Hofman, P. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384121 · Cited by 34
The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non–Small Cell Lung Cancer
Shukuya, T., Yamada, T., Koenig, M. J., Xu, J., Okimoto, T., Li, F., Amann, J. M., & Carbone, D. P. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.019 · Cited by 31
“However, LKB1 genomic alterations are associated with primary resistance to PD-1/PD-L1 blockade therapy in NSCLC [4].”
BackgroundTian, Y., Xu, J., Chu, Q., Duan, J., Zhang, J. J., Bai, H., Yang, Z., Fang, W., Cai, L., Wan, R., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01694-8 · Cited by 30
Self-citationIndependent Prognostic Potential of GNPNAT1 in Lung Adenocarcinoma
Zheng, X., Li, Y., Ma, C., Zhang, J., Zhang, Y., Fu, Z., & Luo, H. (2020) · BioMed Research International · doi:10.1155/2020/8851437 · Cited by 30
“STK11, mutated or deleted in a third of non-small-cell lung cancer patients, fosters an immunologically “ cold ” tumor microenvironment, with minimal penetration of tumors by T cells, rendering anti-PD1/PDL1 drugs ine ff ective [36].”
Self-citationDong, A., Zhao, Y., Li, Z., & Hu, H. (2020) · The Journal of Gene Medicine · doi:10.1002/jgm.3294 · Cited by 31
“Improved ORR was also found in co-mutant patients.(139,141) Additionally, subtypes with the KRAS”
BackgroundTesta, U., Pelosi, E., & Castelli, G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017774 · Cited by 31
“These observations support the view that the exploration of TP53 and STK11, as well as the assessment of gene expression profiling, in addition to evaluation of PD-L1 expression, represents a potentially important tool for guiding the administration of immune checkpoint blockade therapy for KRAS-mutant LUADs.”
BackgroundInfluentialKonen, J. M., Rodriguez, B. L., Wu, H., Fradette, J. J., Gibson, L., Diao, L., Wang, J., Schmidt, S., Wistuba, I. I., Zhang, J. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163128 · Cited by 36
“Specifically, those with concurrent KRAS and TP53 mutations (termed KP) have an approximately 35% response rate to anti–PD-1 monotherapy, with increased expression of inflammatory signatures and PD-L1 in comparison with other KRAS -mutant subtypes (14, 15).”
Self-citationMolecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
Boiarsky, D., Lydon, C., Chambers, E. S., Sholl, L. M., Nishino, M., Skoulidis, F., Heymach, J. V., Luo, J., Awad, M. M., Janne, P. A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.04.514 · Cited by 35
Self-citationZeng, Y., Huang, Y., Tan, Q., Peng, L., Wang, J., Tong, F., & Dong, X. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13413 · Cited by 34
“In addition to the aforementioned mechanisms, there are numerous studies on other aspects of resistance such as genetic mutations (28), gut microbiota (29) and metabo‑ lism (17).”
Self-citationGe, Y., Zhou, Q., Pan, F., & Wang, R. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505539 · Cited by 30
Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma
Behrens, C., Rocha, P., Parra, E. R., Feng, L., Rodriguez‐Canales, J., Solis, L. M., Mino, B., Zhang, J. J., Gibbons, D. L., Sepesi, B., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.06.003 · Cited by 27
Self-citationEnhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Ward, A., Keeton, A. B., Chen, X., Mattox, T. E., Coley, A. B., Maxuitenko, Y. Y., Buchsbaum, D. J., Randall, T. D., Zhou, G., & Piazza, G. A. (2020) · MedComm · doi:10.1002/mco2.10 · Cited by 29
“are limitations due to resistance and an overall modest success rate among the currently available FDA-approved immunotherapies.(69,70) Targeted therapies that can possibly be used in synergy with immunotherapy drugs are needed for the treatment of aggressive tumors in cancer patients with RAS mutations.”
BackgroundCurrent and future trends in non–small cell lung cancer biomarker testing: The American experience
VanderLaan, P. A., & Roy‐Chowdhuri, S. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22313 · Cited by 30
“In addition, broader NGS-type panel testing can provide valuable information regarding the tumor’s comutational profile, which may help to direct therapeutic choices in the future, such as the identification of inactivating STK11/LKB1 mutations in KRASmutated lung adenocarcinomas, which are predictive of primary resis…”
BackgroundFan, T. T., Zhu, M., Wang, L., Liu, Y., Tian, H., Zheng, Y., Tan, F., Sun, N., Li, C., & He, J. (2020) · Aging · doi:10.18632/aging.202269 · Cited by 31
Comprehensive tumor molecular profile analysis in clinical practice
Özdoğan, M., Papadopoulou, E., Τσούλος, Ν., Tsantikidi, A., Mariatou, V.-M., Tsaousis, G., Kapeni, E., Bourkoula, E., Fotiou, D. F., Kapetsis, G., et al. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-00952-9 · Cited by 31
TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma
Zhong, A., Chen, T., Zhou, T., Zhang, Z., & Shi, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728420 · Cited by 27
Wang, Z., Lu, C., Zhang, K., Lin, C., Wu, F., Tang, X., Wu, D., Dou, Y., Han, R., Wang, Y., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.780200 · Cited by 40
LKB1: Can We Target an Hidden Target? Focus on NSCLC
Ndembe, G., Intini, I., Perin, E., Marabese, M., Caiola, E., Mendogni, P., Rosso, L., Broggini, M., & Colombo, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.889826 · Cited by 34
“LKB1 inactivation in NSCLC is associated with a reduction of CD8+ T lymphocytes and a higher density of the immune-suppressive cell population, defining an “inert” or cold tumor immune microenvironment, that promotes resistance to PD-1/PD-L1 inhibitors (43, 50).”
BackgroundNakahama, K., Kaneda, H., Osawa, M., Izumi, M., Yoshimoto, N., Sugimoto, A. K., Nagamine, H., Ogawa, K., Matsumoto, Y., Sawa, K., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14560 · Cited by 41
Isaksson, J., Berglund, A., Louie, K. S., Willén, L., Hamidian, A., Edsjö, A., Enlund, F., Planck, M., Vikström, A., Johansson, M., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.05.002 · Cited by 31
“14 , 15 The first KRAS p.G12C targeted therapy has been approved for patients with disease progression after first line systemic treatment.”
Manolakos, P., & Ward, L. D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061010 · Cited by 27
“This is in stark contrast to a previous, widely cited analysis (N = 174) pointing to the negative predictive effect of STK11 co-mutations as a major driver of primary resistance in relation to ICI [13].”
BackgroundResultInfluentialWhole-Exome Profiling of NSCLC Among African Americans
Arauz, R. F., Byun, J. S., Tandon, M., Sinha, S., Kuhn, S. A., Taylor, S., Zingone, A., Mitchell, K. A., Pine, S. R., Gardner, K. L., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.08.029 · Cited by 27
Otegui, N., Houry, M., Arozarena, I., Serrano, D., Redín, E., Expósito, F., León, S., Valencia, K., Montuenga, L. M., & Calvo, A. (2023) · Cancers · doi:10.3390/cancers15123076 · Cited by 30
“In NSCLC models, Redin et al. have demonstrated a synergistic antitumor effect between dasatinib and anti-PD-1, with a reduction in the number of Tregs and an increase in CD4+ and CD8+ T cells.”
BackgroundInfluentialGalán‐Cobo, A., Vokes, N. I., Qian, Y., Molkentine, D. P., Ramkumar, K., Paula, A. G., Pisegna, M. A., McGrail, D. J., Poteete, A., Cho, S.-N., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.06.011 · Cited by 38
Self-citationPAK4 as a cancer immune-evasion target
Gajewski, T. F., & Fessler, J. L. (2020) · Nature Cancer · doi:10.1038/s43018-019-0012-z · Cited by 26
Chemokine biology on immune checkpoint–targeted therapies
Letourneur, D., Danlos, F., & Marabelle, A. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.009 · Cited by 29
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer
Zhou, Q., Chen, W., Fan, Z., Chen, Z., Liang, J., Zeng, G., Liu, L., Liu, W., Yang, T., Cao, X., et al. (2021) · Theranostics · doi:10.7150/thno.59816 · Cited by 24
“There is increasing evidence that dysfunction of TSGs severely impacts response of cancer cells to chemotherapy [1], targeted therapy [2] and immunotherapy [3].”
BackgroundGalland, L., Page, A. L. L., Lecuelle, J., Bibeau, F., Oulkhouir, Y., Dérangère, V., Truntzer, C., & Ghiringhelli, F. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1957603 · Cited by 32
“Moreover, presence of LKB1 loss is reported to be associated with a lack of efficacy of immunotherapy in KRAS lung adenocarcinoma.(58) This is why, in an exploratory data set, we analyzed LKB1 expression on 100 patients, 50 with TTF1+ and 50 with TTF1-.”
BackgroundSun, Y., Duan, J., Fang, W., Wang, Z., Du, X., Wang, X., Li, C., Cai, S., Zhao, J., Li, S., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02075-5 · Cited by 29
“Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma.”
BackgroundInfluentialSelf-citationMeraz, I. M., Majidi, M., Shao, R., Meng, F., Ha, M. J., Shpall, E. J., & Roth, J. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03103-7 · Cited by 28
Emerging Blood-Based Biomarkers for Predicting Immunotherapy Response in NSCLC
Oitabén, A., Fonseca, P., Villanueva, M. J., García-Benito, C., López‐López, A., Fernández, A. G., González-Ojea, C., Juaneda‐Magdalena, L., Lázaro, M. E., & Martínez‐Fernández, M. (2022) · Cancers · doi:10.3390/cancers14112626 · Cited by 28
“Intriguingly, STK11 mutations are often associated with KRAS mutation [67], and it has been reported that STK11/KRAS co-mutations cause worse survival outcomes in ICI-treated patients [69].”
BackgroundMolecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 30
Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors
Zhou, X., Ji, Y., & Zhou, J. (2023) · Molecules · doi:10.3390/molecules28083615 · Cited by 29
“Moreover, KRAS mutations often combine with specific comutations in TP53, STK11, or KEAP1, etc., which modulate the function of KRAS and lead to oncogenesis [38,42].”
BackgroundInfluentialTumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
Laubach, K., Turan, T., Mathew, R. S., Wilsbacher, J. L., Engelhardt, J., & Samayoa, J. A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.60 · Cited by 33
Li, Z., Guo, M., Lin, W., & Huang, P. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102897 · Cited by 27
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
Giglio, A. D., de Biase, D., Favorito, V., Maloberti, T., Federico, A. D., Zacchini, F., Venturi, G., Parisi, C., Dall’Olio, F. G., Ricciotti, I., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108058 · Cited by 41
Chen, Z., Fan, Z., Dou, X., Zhou, Q., Zeng, G., Liu, L., Chen, W., Lan, R., Liu, W., Ru, G., et al. (2020) · Theranostics · doi:10.7150/thno.44829 · Cited by 25
“that status of tumor suppressor genes significantly impacted the efficacy of precision medicine, including chemotherapy [1], targeting therapy [2] and immunotherapy [3].”
BackgroundLee, J., Tan, A. C., Zhou, S., Yoon, S., Liu, S. M., Masuda, K., Hayashi, H., Batra, U., Kim, D., Goto, Y., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100261 · Cited by 27
“Most interestingly, patients with STK11 or LKB1 co-mutations are associated with lower T cell infiltration and PD-L1 expression, even in tumors with a high tumor mutational burden.(35) They exhibited significantly shorter PFS and OS with immunotherapy compared with patients with TP53 or CDKN2A/B comutations, regardles…”
BackgroundSelf-citationVelcheti, V., Hu, X., Li, Y., El-Osta, H. E., Pietanza, M. C., & Burke, T. A. (2022) · Cancers · doi:10.3390/cancers14041041 · Cited by 29
“These findings are aligned with those of others who reported no differences in the effectiveness of first-line ICI therapy according to KRAS mutation status [9,10], although a concomitant STK11 mutation was found to be associated with PD-1 inhibitor resistance and worse clinical outcomes [38].”
ResultLi, J., Xue, X., Zhang, Y., Ding, F., Wu, W., Liu, C., Xu, Y., Chen, H., Ou, Q., Shao, Y. W., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.05.071 · Cited by 25
Zhao, D., Li, H., Mambetsariev, I., Mirzapoiazova, T., Chen, C., Fricke, J., Kulkarni, P., Villaflor, V., Arvanitis, L., Hamilton, S., et al. (2022) · Cancers · doi:10.3390/cancers14194933 · Cited by 24
“The comutation of STK11/LKB1 and the comutation of KEAP1/NFE2L2 were identified as genomic drivers for primary resistance to immune checkpoint inhibitors in KRAS-mutated lung adenocarcinoma [38,39].”
BackgroundNon–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Frost, N., & Reck, M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432524 · Cited by 26
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies
Liguori, L., Salomone, F., Viggiano, A., Sabbatino, F., Pepe, S., Formisano, L., Bianco, R., & Servetto, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104554 · Cited by 31
RNA sensing induced by chromosome missegregation augments anti-tumor immunity
Sasaki, N., Homme, M., Murayama, T., Osaki, T., Tenma, T., An, T., Takegami, Y., Tani, T., Gedeon, P. C., Kobayashi, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.11.025 · Cited by 36
Tian, L., Li, H., Cui, H., Tang, C., Zhao, P., Wang, X., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08101-1 · Cited by 31
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.